Skip to Content

Avutometinib and Defactinib (Avmapki Fakzynja Co-Pack) for the Management of KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)

Download PQI pdf

Last Updated: October 6, 2026

By: Sarah Hayward, PharmD, BCOP

About this PQI

For patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), avutometinib + defactinib introduces a unique treatment approach—and a few practical considerations oncology teams will want to have on their radar.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI